Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tonix Pharm Holdings (TNXP)

Tonix Pharm Holdings (TNXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 197,677
  • Shares Outstanding, K 11,777
  • Annual Sales, $ 10,090 K
  • Annual Income, $ -130,040 K
  • EBIT $ -100 M
  • EBITDA $ -96 M
  • 60-Month Beta 1.82
  • Price/Sales 19.58
  • Price/Cash Flow N/A
  • Price/Book 0.74

Options Overview Details

View History
  • Implied Volatility 122.59% (-6.51%)
  • Historical Volatility 81.49%
  • IV Percentile 16%
  • IV Rank 15.00%
  • IV High 184.77% on 09/05/25
  • IV Low 111.61% on 12/11/25
  • Expected Move (DTE 21) 3.49 (21.43%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 192
  • Volume Avg (30-Day) 288
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 2,338
  • Open Int (30-Day) 3,414
  • Expected Range 12.78 to 19.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -3.16
  • Number of Estimates 3
  • High Estimate -2.85
  • Low Estimate -3.65
  • Prior Year -9.77
  • Growth Rate Est. (year over year) +67.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.10 +7.68%
on 12/02/25
20.56 -20.91%
on 12/12/25
+1.18 (+7.82%)
since 11/26/25
3-Month
13.70 +18.69%
on 11/25/25
25.52 -36.29%
on 09/29/25
-7.95 (-32.84%)
since 09/26/25
52-Week
6.76 +140.53%
on 03/04/25
69.97 -76.76%
on 08/14/25
-20.74 (-56.05%)
since 12/26/24

Most Recent Stories

More News
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University

Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic pain Compelling safety and pharmacokinetic profiles in animals support IND-enabling...

TNXP : 16.26 (-3.13%)
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

CHATHAM, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated commercial-stage biotechnology company today...

TNXP : 16.26 (-3.13%)
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026 More than 21 million US adults experience a major depressive episode...

TNXP : 16.26 (-3.13%)
Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment

TONMYA is now available by prescription and available for pharmacy ordering nationwide TONMYA is the first FDA-approved treatment for fibromyalgia in more than 15 years TONMYA is a unique, non-opioid,...

TNXP : 16.26 (-3.13%)
Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia set to launch in November Tonmya is the first new FDA-approved medicine for fibromyalgia in more than 15 years...

TNXP : 16.26 (-3.13%)
Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference

CHATHAM, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biotechnology company, today announced...

TNXP : 16.26 (-3.13%)
Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

Planning to initiate an open-label Phase 2 study of TNX-1500 under an investigator-initiated IND to evaluate safety and activity in the first half of 2026    Novel immunomodulatory regimen designed...

TNXP : 16.26 (-3.13%)
Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025

CHATHAM, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biopharmaceutical company announced...

TNXP : 16.26 (-3.13%)
Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Treatment was well tolerated with minimal effects on weight or blood pressure and...

TNXP : 16.26 (-3.13%)
Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix’s investigational intranasal potentiated oxytocin products in patients with Arginine-Vasopressin Deficiency...

TNXP : 16.26 (-3.13%)

Business Summary

Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102,...

See More

Key Turning Points

3rd Resistance Point 17.42
2nd Resistance Point 17.05
1st Resistance Point 16.66
Last Price 16.26
1st Support Level 15.90
2nd Support Level 15.53
3rd Support Level 15.14

See More

52-Week High 69.97
Fibonacci 61.8% 45.82
Fibonacci 50% 38.37
Fibonacci 38.2% 30.91
Last Price 16.26
52-Week Low 6.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar